STGEN Bio bets W110b on biologics capacity expansion
--------------------------------------------------------------------
Source: The Korea Herald
Published: 2026-03-13 12:15 UTC+10:00
Section: All News
Factuality Score: 100
Opinion Category: Neutral
Topics: Property, South Korea, Financial Markets, World News
--------------------------------------------------------------------
Snippet:
STGEN Bio, a South Korean biopharmaceutical contract development and manufacturing organization, said Friday it will invest about 110 billion won ($82 million) to expand its biopharmaceutical manufacturing facilities, aiming to strengthen its global position amid rising demand for biologics.
--------------------------------------------------------------------